Disparities in pediatric oncology access and outcomes in the occupied Palestinian territories: a retrospective study from Augusta Victoria Hospital.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
BACKGROUND: Childhood cancer survival rates are lower in low- and middle-income countries, with additional challenges in the occupied Palestinian territories (OPT) due to political instability. This study reports outcomes of children treated at Augusta Victoria Hospital (AVH), the only dedicated cancer center in the OPT. METHODS: A retrospective chart review analyzing diagnoses, treatments, and outcomes of pediatric oncology patients admitted to AVH between January 2018 and June 2024. FINDINGS: Among 424 patients (West Bank: 51.2%, Gaza: 43.4%, East Jerusalem: 3.8%), the median diagnostic delay was 24.5 days (IQR, 10-45), with significant variation by gender (males: 30 days; females: 20 days, p = 0.018), age group (<5 years: 14 days; >10 years: 30 days, p = 0.003), and oncology diagnosis (leukemia: 14 days, lymphoma and solid tumors: 30 days, p = 0.011). Median Treatment delay was 14 days (IQR, 4-30), with the shortest duration for leukemia (2 days) and the longest for solid tumors (30 days, p = 0.0008). Most patients lost to follow-up (LTFU) were living in Gaza (15/21, 71.4%). Among the 12.5% deaths, 15.1% were treatment-related, primarily due to infection, and most of these treatment-related deaths (62.5%) occurred in patients living in Gaza. The 3-year overall survival (OS) was 76.99%, and event-free survival (EFS) was 62.91% with significant regional differences in OS (p = 0.0065) and EFS (p < 0.0001). Gaza patients had the lowest OS (64.47%) and EFS (38.18%), compared to the West Bank (OS: 81.69%, EFS: 70.77%) and East Jerusalem (77.78%). INTERPRETATION: This study is the first to report on outcomes of pediatric oncology patients treated at AVH. Males and patients older than 10 years experienced longer diagnostic delays, while patients with solid tumors faced treatment delays 15 times longer than those with leukemia. Gaza patients had higher LTFU rates and treatment-related deaths with significantly inferior survival. FUNDING: No funding was received.